{
  "metadata": {
    "case_id": 35,
    "model": "Gemini-3-Pro",
    "timestamp": "2025-11-29T15:55:24.758392",
    "total_alignments": 4,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/35_NCT03019588.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/Gemini-3-Pro/35_Gemini-3-Pro.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.99,
          0.4
        ],
        [
          0.4,
          0.97
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.99,
          "status": "matched",
          "ref_item": {
            "label": "Pembrolizumab 200 mg",
            "type": "EXPERIMENTAL",
            "description": "Participants receive pembrolizumab 200 mg intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles (up to approximately 2 years).",
            "interventionNames": [
              "Biological: Pembrolizumab"
            ]
          },
          "pred_item": {
            "label": "Pembrolizumab",
            "type": "EXPERIMENTAL",
            "description": "Participants received 200 mg of pembrolizumab intravenously every 3 weeks for up to 2 years (35 cycles).",
            "interventionNames": [
              "Drug: Pembrolizumab"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.97,
          "status": "matched",
          "ref_item": {
            "label": "Paclitaxel 80 mg/m^2",
            "type": "ACTIVE_COMPARATOR",
            "description": "Participants receive paclitaxel 80 mg/m\\^2 IV infusion on Days 1, 8 and 15 of each 4-week cycle for up to approximately 2 years.",
            "interventionNames": [
              "Drug: Paclitaxel"
            ]
          },
          "pred_item": {
            "label": "Paclitaxel",
            "type": "ACTIVE_COMPARATOR",
            "description": "Participants received 80 mg/m^2 of paclitaxel intravenously on days 1, 8, and 15 of each 4-week cycle.",
            "interventionNames": [
              "Drug: Paclitaxel"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.96,
          0.1
        ],
        [
          0.4,
          0.98
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "type": "BIOLOGICAL",
            "name": "Pembrolizumab",
            "description": "IV infusion",
            "armGroupLabels": [
              "Pembrolizumab 200 mg"
            ],
            "otherNames": [
              "MK-3475"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Pembrolizumab",
            "description": "Administered intravenously at a dose of 200 mg every 3 weeks.",
            "armGroupLabels": [
              "Pembrolizumab"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.98,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Paclitaxel",
            "description": "IV infusion",
            "armGroupLabels": [
              "Paclitaxel 80 mg/m^2"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Paclitaxel",
            "description": "Administered intravenously at a dose of 80 mg/m^2 on days 1, 8, and 15 of each 4-week cycle.",
            "armGroupLabels": [
              "Paclitaxel"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.99,
          0.55
        ],
        [
          0.35,
          0.97
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.99,
          "status": "matched",
          "ref_item": {
            "measure": "Overall Survival (OS)",
            "description": "OS is defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up.",
            "timeFrame": "Up to approximately 50 months"
          },
          "pred_item": {
            "measure": "Overall Survival (OS)",
            "description": "Time from randomization to death from any cause.",
            "timeFrame": "From randomization until death from any cause, assessed up to approximately 4 years"
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.97,
          "status": "matched",
          "ref_item": {
            "measure": "Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)",
            "description": "PFS is defined as the time from randomization to the first documented disease progression or death due to any cause, whichever occurs first. Per RECIST 1.1, progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Note: The appearance of one or more new lesions was also considered progression. PFS as assessed by blinded independent central review will be presented.",
            "timeFrame": "Up to approximately 50 months"
          },
          "pred_item": {
            "measure": "Progression-Free Survival (PFS)",
            "description": "Time from randomization to the first documented disease progression or death from any cause, whichever occurred first, assessed according to RECIST v1.1 by blinded central radiology review.",
            "timeFrame": "Assessed every 6 weeks"
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.secondaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 3,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.94,
          0.12
        ],
        [
          0.08,
          0.86
        ],
        [
          0.08,
          0.7
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.94,
          "status": "matched",
          "ref_item": {
            "measure": "Objective Response Rate (ORR) Per RECIST 1.1",
            "description": "ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1.",
            "timeFrame": "Up to approximately 50 months"
          },
          "pred_item": {
            "measure": "Objective Response Rate (ORR)",
            "description": "The proportion of patients who experienced complete or partial response assessed according to RECIST v1.1.",
            "timeFrame": "Assessed every 6 weeks"
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.86,
          "status": "matched",
          "ref_item": {
            "measure": "Number of Participants Who Experience an Adverse Event (AE)",
            "description": "An adverse event is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.",
            "timeFrame": "Up to approximately 50 months"
          },
          "pred_item": {
            "measure": "Safety and Tolerability",
            "description": "Assessment of adverse events (AEs) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.",
            "timeFrame": "Throughout treatment and for 30 days after treatment discontinuation (90 days for serious AEs)"
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Number of Participants Who Discontinue Study Treatment Due to an AE",
            "description": "An adverse event is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.",
            "timeFrame": "Up to approximately 25 months"
          },
          "pred_item": null
        }
      ]
    }
  ]
}